Over the past years, the CXCR4/CXCL12 cascade has been a significant therapeutic target in lung cancer since it offers a major function in cancer development, metastasis, immunological evasion, and resistance to treatment (Wang et al., 2016; Wald, 2018). This evidence concerns the gene CXCR4 and lung carcinoma.